BPC-157 vs TB-500
BPC-157 and TB-500 are the two peptides most often discussed together in tissue-repair research, and they are frequently confused for one another. They come from different parent molecules and work through different mechanisms, yet both are studied for angiogenesis and recovery. Here is how they compare across mechanism, reported dosing, and pharmacology.
| BPC-157 | TB-500 | |
|---|---|---|
| Class | Stable synthetic pentadecapeptide (15 amino acids) derived from a gastric juice protein | Synthetic peptide fragment related to the protein thymosin beta-4 |
| Primary mechanism | Promotes angiogenesis via VEGFR2 and the nitric oxide system; cytoprotective | Sequesters actin to drive cell migration and angiogenesis |
| Reported half-life | Short (minutes); rapidly cleared | Longer-acting than BPC-157 |
| Reported research dosing | ~200-500 mcg/day, often split into two doses | ~2-2.5 mg once or twice weekly loading, then a tapered maintenance dose |
| Route / frequency | Subcutaneous or oral in references; typically daily | Subcutaneous or intramuscular; 1-2x per week |
| Action profile | More localized; often referenced for gut and connective-tissue repair | More systemic distribution across the body |
| Regulatory / anti-doping status | Research-use-only, not approved; WADA Prohibited (S0, added 2022) | Research-use-only, not approved; WADA Prohibited (S2) |
| Best studied for | Tendon, ligament, and gastrointestinal repair models | Systemic tissue-repair and wound-healing models |
BPC-157
BPC-157 is most referenced in preclinical models of tendon, ligament, and gastrointestinal healing, where its cytoprotective and angiogenic effects are studied at low daily microgram doses.
Full BPC-157 profile →TB-500
TB-500 is most referenced for broader, systemic tissue-repair and cell-migration research, dosed in larger milligram amounts a couple of times per week.
Full TB-500 profile →The bottom line
Both remain research-use-only peptides with no large human trials and are prohibited in sport, so neither is a clinical treatment. In the research community they are often viewed as complementary rather than competing — BPC-157 for more localized repair and TB-500 for systemic coverage — which is why they are commonly studied together. This is educational information, not medical advice.
Educational summary only. Dosing and effects describe how these compounds appear in the research literature — not a recommendation for human use. For laboratory research use only.
BPC-157 vs TB-500 FAQ
What is the difference between BPC-157 and TB-500?
BPC-157 is a stable pentadecapeptide derived from a gastric protein that acts largely through VEGFR2 and nitric oxide signaling and is referenced for more localized repair, while TB-500 is a thymosin beta-4-related fragment that works by sequestering actin to promote cell migration, with a longer-acting and more systemic profile.
Can you take BPC-157 and TB-500 together?
In research and anecdotal community references the two are frequently combined (sometimes nicknamed a ‘Wolverine’ stack) because they act through different mechanisms. However, both are research-use-only, unapproved, and prohibited in sport, and no controlled human data establish the safety of the combination — this is not a recommendation.
How are BPC-157 and TB-500 dosed in the literature?
Research references typically cite roughly 200-500 mcg of BPC-157 per day (often split), versus about 2-2.5 mg of TB-500 once or twice weekly during a loading phase followed by a taper. These are reported research figures, not medical dosing guidance.
Are BPC-157 and TB-500 approved or legal?
Neither is approved by the FDA for human use; both are sold and handled as research-use-only compounds and both appear on the WADA Prohibited List (BPC-157 under S0, thymosin beta-4/TB-500 under S2), so they are banned for athletes.